In clinical trials, doses of up to 1,000 mg have been administered intravenously in patients with SLE with no evidence of dose limiting toxicities.
There is no specific treatment for an overdose with anifrolumab. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.